Aptinyx Inc. (APTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
APTX Stock Price Chart Interactive Chart >
APTX Price/Volume Stats
| Current price | $0.28 | 52-week high | $3.76 |
| Prev. close | $0.28 | 52-week low | $0.20 |
| Day low | $0.27 | Volume | 43,800 |
| Day high | $0.29 | Avg. volume | 350,609 |
| 50-day MA | $0.33 | Dividend yield | N/A |
| 200-day MA | $1.00 | Market Cap | 19.29M |
Aptinyx Inc. (APTX) Company Bio
Aptinyx Inc. develops therapeutics for neurological disorders. The company is focused on the development of drugs that interact with the NMDA receptor, and the company says it will use the funds to advance drugs for chronic pain, post-traumatic stress disorder (PTSD) and cognitive impairment in Parkinson’s disease. The company was founded in 2015 and is based in Evantson, Illinois.
Latest APTX News From Around the Web
Below are the latest news stories about APTINYX INC that investors may wish to consider to help them evaluate APTX as an investment opportunity.
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for NeuroscienceEVANSTON, Ill., November 10, 2022--Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations at the 52nd Annual Meeting of the Society for Neuroscience being held November 12-16, 2022 in San Diego, CA. The presentations include preclinical data supporting the development of NYX-783, an NMDA receptor positive allosteric modulator in post-traumatic |
BMO Capital Remains a Buy on Aptinyx (APTX)In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on Aptinyx (APTX - Research Report), with a price target of $2.00. The company's shares opened today at $0.31.Nachman covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Horizon Therapeutics, and AbbVie. According to TipRanks, Nachman has an average return of -9.1% and a 40.76% success rate on recommended stocks. Currently, the analyst consensus on Aptinyx is a Moderate Buy with an average price target of $1.67.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $3.76 and a one-year low of $0.20. |
Aptinyx Reports Third Quarter 2022 Financial Results and Recent HighlightsEVANSTON, Ill., November 08, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators. |
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH GrantEVANSTON, Ill., November 03, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, supporting the development of NYX-783 for the treatment of opioid use disorder (OUD). NYX-783 is an NMDA receptor positive allosteric modulator also in P |
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022EVANSTON, Ill., October 18, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. |
APTX Price Returns
| 1-mo | 0.00% |
| 3-mo | -29.98% |
| 6-mo | N/A |
| 1-year | -88.43% |
| 3-year | -92.80% |
| 5-year | N/A |
| YTD | -89.51% |
| 2021 | -22.83% |
| 2020 | 1.17% |
| 2019 | -79.32% |
| 2018 | N/A |
| 2017 | N/A |
Continue Researching APTX
Want to see what other sources are saying about Aptinyx Inc's financials and stock price? Try the links below:Aptinyx Inc (APTX) Stock Price | Nasdaq
Aptinyx Inc (APTX) Stock Quote, History and News - Yahoo Finance
Aptinyx Inc (APTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...